Study flags dye interference risk in fluorescence-guided node mapping

A new paper in Animals puts a sharper lens on a practical question in fluorescence-guided veterinary oncology: what happens when surgeons combine methylene blue with indocyanine green for sentinel lymph node mapping. The study, titled When Blue Turns the Green Off, examined whether methylene blue can dampen indocyanine green’s near-infrared signal and found evidence consistent with fluorescence quenching, a finding that could affect how reliably teams visualize lymphatic drainage and sentinel nodes during surgery. That matters because indocyanine green-guided mapping is gaining ground in dogs and cats as a real-time staging tool. (pubmed.ncbi.nlm.nih.gov)

The backdrop is a fast-moving shift in veterinary surgical oncology toward more precise nodal staging. Over the past several years, studies have described near-infrared indocyanine green mapping in healthy dogs, case-level and pilot applications in canine cancers, and combined strategies that pair preoperative imaging with intraoperative dyes. In a 2025 pilot study in dogs with thyroid carcinoma, investigators used both methylene blue and indocyanine green intraoperatively after CT lymphography, reflecting the kind of multimodal workflow now entering practice. Separate recent work has also reported methylene blue as a standalone, cost-effective mapping option in dogs with low-grade mast cell tumors. More broadly, methylene blue remains appealing to clinicians because it is inexpensive, familiar, and pharmacologically active in ways that extend beyond surgical staining. A recent Animals study in Nile tilapia, for instance, found that methylene blue incorporated into feed protected fish during acute nitrite intoxication: none of the methylene blue-fed fish died, compared with five deaths in controls, methemoglobin concentrations were lower, and gill histology showed milder lesions with preserved lamellae rather than the aneurysm, edema, congestion, fusion, and epithelial hyperplasia seen in untreated fish. That aquaculture paper is not about oncology imaging, but it reinforces why methylene blue keeps showing up across veterinary contexts—as a practical dye with clinically meaningful biologic effects. (pubmed.ncbi.nlm.nih.gov)

Against that background, the new Animals study is a protocol warning. Based on the abstract and related fluorescence literature, the authors quantitatively and qualitatively assessed methylene blue–indocyanine green mixtures at different ratios across three near-infrared imaging modalities, looking for signal loss. While the full clinical implications still need to be worked out, the underlying mechanism is plausible: both dyes have known fluorescence behavior that can be concentration- and environment-dependent, and quenching is a recognized issue in optical imaging. Human surgical literature has already noted that methylene blue’s own fluorescence performance can be limited by quenching effects, and broader imaging reviews describe both indocyanine green and methylene blue as established fluorophores whose behavior depends heavily on dose, timing, and imaging setup. The tilapia study adds a useful reminder that methylene blue’s value in practice often comes from its redox and antidotal properties, including mitigation of methemoglobinemia, not just from its visibility as a tracer—so a dye that is clinically helpful in one context may still create technical tradeoffs in another. (pubmed.ncbi.nlm.nih.gov)

At the same time, another paper highlighted in your source set points in a different but related direction: expanding access. The JAVMA study on 10% fluorescein sodium in dogs evaluated a low-cost intraoperative sentinel lymph node mapping approach, building on older veterinary work showing fluorescein can identify lymphatic channels and nodes in dogs. While I wasn’t able to retrieve the full JAVMA article text directly from indexed sources, the study’s framing fits a broader pattern in the field: teams are looking for mapping methods that are practical, visible in real time, and financially realistic for more pet parents. That same practicality theme is visible in the tilapia methylene blue feed study, where investigators were trying to move beyond injections or immersion baths toward a scalable oral intervention for nitrite emergencies in recirculating aquaculture systems. In both cases, the underlying question is similar: can a familiar dye be deployed in a way that is both effective and operationally realistic? That makes any limitation of indocyanine green–methylene blue combinations more than a technical footnote; it could influence which workflows are considered scalable in general practice and referral settings. (pubmed.ncbi.nlm.nih.gov)

Industry and expert reaction appears to be emerging more through the literature than through formal commentary. Recent veterinary studies have emphasized the clinical value of accurate sentinel lymph node identification for staging and biopsy selection, especially in canine mammary tumors and thyroid carcinoma. Human surgical guidance likewise treats fluorescence imaging as useful but protocol-sensitive, with performance shaped by tracer choice, concentration, and timing. Taken together, that suggests the new Animals paper will likely be read as a methods paper with immediate practical implications rather than as a reason to step back from fluorescence-guided surgery altogether. That last point is an inference based on the current literature trend, not a direct quote from a single expert source. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is really about signal integrity and decision quality. If methylene blue weakens indocyanine green fluorescence in clinically relevant mixtures, surgeons could miss a lymphatic tract, underestimate node uptake, or change dissection plans based on an artifact rather than anatomy. In a field where sentinel node mapping is increasingly used to improve staging accuracy and tailor surgery, that kind of interference could affect both case selection and intraoperative confidence. It also sharpens the conversation around lower-cost tracers, including methylene blue alone or fluorescein sodium, for practices balancing access, equipment limitations, and diagnostic performance. And because methylene blue continues to prove useful in other veterinary settings—such as reducing methemoglobinemia and tissue injury during nitrite intoxication in fish—it is unlikely to disappear from practice; instead, clinicians may need to become more selective about when they use it as a therapeutic agent, a visible dye, or a fluorescence partner. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next step is clinical validation. Watch for prospective veterinary studies comparing dual-tracer, single-tracer, and fluorescein-based protocols in live oncology patients, with attention to detection rate, false negatives, ease of use, adverse events, and cost. Also worth watching is whether authors or specialty groups begin recommending specific sequencing, dilution, or camera-setting adjustments when methylene blue and indocyanine green are used in the same case. Beyond oncology, the tilapia feed study also points to another likely research direction for methylene blue more generally: dose-response work, post-exposure rescue protocols, tissue residue questions, and clearer guidance on how to scale administration methods without losing efficacy. (pubmed.ncbi.nlm.nih.gov)